Skip to main content
Erschienen in: World Journal of Surgery 6/2018

07.12.2017 | Original Scientific Report

Long-Term Survival of Recurrent Intrahepatic Cholangiocarcinoma: The Impact and Selection of Repeat Surgery

verfasst von: Tomoaki Yoh, Etsuro Hatano, Satoru Seo, Yukihiro Okuda, Hiroaki Fuji, Yoshinobu Ikeno, Kojiro Taura, Kentaro Yasuchika, Hideaki Okajima, Toshimi Kaido, Shinji Uemoto

Erschienen in: World Journal of Surgery | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Definitive guidelines for recurrent intrahepatic cholangiocarcinoma (ICC) do not exist. This study has focused on the repeat surgery when analyzing the survival outcomes of recurrent ICC. We evaluated the relationship between clinicopathological features of the primary tumor and implementation of the repeat surgery to identify its potential selection criteria.

Methods

A total of 108 patients with recurrent ICC between 1993 and 2015 were analyzed. Of these, 15 patients underwent repeat surgery and 93 did not.

Results

Seven out of 29 patients with intrahepatic recurrence and eight out of 44 patients with extrahepatic recurrence were amenable to the repeat surgery. Thirty-five patients with simultaneous or consequent intrahepatic recurrence and extrahepatic recurrence were not amenable to the repeat surgery. Patients who underwent repeat surgery had a lower proportion of lymph node metastases (n = 0 [0%] vs. n = 47 [50.5%], p < 0.001), multiple tumors in the primary tumor (n = 1 [6.7%] vs. n = 31 [33.3%], p = 0.037), or early recurrence (≤ 1 year; n = 4 [26.7%] vs. n = 62 [66.7%], p = 0.003). Survival after recurrence (SAR) was better in patients who underwent repeat surgery than in those who did not (median SAR time: 91.6 vs. 10.4 months, and 3-year survival: 86.7 vs. 8.7%, respectively, p < 0.001).

Conclusions

Repeat surgery for recurrent ICC with an appropriate selection can be associated with prolonged survival. Regarding the feasibility, nodal status, number of tumors on the primary tumor, and time to recurrence may be considered as selection criteria.
Literatur
1.
Zurück zum Zitat Aljiffry M, Abdulelah A, Walsh M et al (2009) Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 208:134–147CrossRefPubMed Aljiffry M, Abdulelah A, Walsh M et al (2009) Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 208:134–147CrossRefPubMed
2.
Zurück zum Zitat Kudo M, Izumi N, Ichida T et al (2016) Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res 46:372–390CrossRefPubMed Kudo M, Izumi N, Ichida T et al (2016) Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res 46:372–390CrossRefPubMed
3.
Zurück zum Zitat Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289CrossRefPubMed Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289CrossRefPubMed
4.
5.
Zurück zum Zitat Jiang W, Zeng ZC, Tang ZY et al (2011) A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol 22:1644–1652CrossRefPubMed Jiang W, Zeng ZC, Tang ZY et al (2011) A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol 22:1644–1652CrossRefPubMed
6.
Zurück zum Zitat Roayaie S, Guarrera JV, Ye MQ et al (1998) Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg 187:365–372CrossRefPubMed Roayaie S, Guarrera JV, Ye MQ et al (1998) Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg 187:365–372CrossRefPubMed
7.
Zurück zum Zitat Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281CrossRefPubMed Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281CrossRefPubMed
9.
Zurück zum Zitat Ercolani G, Vetrone G, Grazi GL et al (2010) Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg 252:107–114CrossRefPubMed Ercolani G, Vetrone G, Grazi GL et al (2010) Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg 252:107–114CrossRefPubMed
10.
Zurück zum Zitat Si A, Li J, Xing X et al (2017) Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: factors associated with long-term outcomes. Surgery 161:897–908CrossRefPubMed Si A, Li J, Xing X et al (2017) Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: factors associated with long-term outcomes. Surgery 161:897–908CrossRefPubMed
11.
Zurück zum Zitat Park HM, Yun SP, Lee EC et al (2016) Outcomes for patients with recurrent intrahepatic cholangiocarcinoma after surgery. Ann Surg Oncol 23:4392–4400CrossRefPubMed Park HM, Yun SP, Lee EC et al (2016) Outcomes for patients with recurrent intrahepatic cholangiocarcinoma after surgery. Ann Surg Oncol 23:4392–4400CrossRefPubMed
12.
Zurück zum Zitat Spolverato G, Kim Y, Alexandrescu S et al (2016) Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol 23:235–243CrossRefPubMed Spolverato G, Kim Y, Alexandrescu S et al (2016) Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol 23:235–243CrossRefPubMed
13.
Zurück zum Zitat Souche R, Addeo P, Oussoultzoglou E et al (2016) First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma. Am J Surg 212:221–229CrossRefPubMed Souche R, Addeo P, Oussoultzoglou E et al (2016) First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma. Am J Surg 212:221–229CrossRefPubMed
14.
Zurück zum Zitat Hyder O, Hatzaras I, Sotiropoulos GC et al (2013) Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 153:811–818CrossRefPubMedPubMedCentral Hyder O, Hatzaras I, Sotiropoulos GC et al (2013) Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 153:811–818CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Zhang SJ, Hu P, Wang N et al (2013) Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 20:3596–3602CrossRefPubMed Zhang SJ, Hu P, Wang N et al (2013) Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 20:3596–3602CrossRefPubMed
16.
Zurück zum Zitat Kamphues C, Seehofer D, Eisele RM et al (2010) Recurrent intrahepatic cholangiocarcinoma: single-center experience using repeated hepatectomy and radiofrequency ablation. J Hepatobiliary Pancreat Sci 17:509–515CrossRefPubMed Kamphues C, Seehofer D, Eisele RM et al (2010) Recurrent intrahepatic cholangiocarcinoma: single-center experience using repeated hepatectomy and radiofrequency ablation. J Hepatobiliary Pancreat Sci 17:509–515CrossRefPubMed
17.
Zurück zum Zitat Minagawa M, Makuuchi M, Takayama T et al (2003) Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003(238):703–710CrossRef Minagawa M, Makuuchi M, Takayama T et al (2003) Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003(238):703–710CrossRef
18.
Zurück zum Zitat Huang ZY, Liang BY, Xiong M et al (2012) Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann Surg Oncol 19:2515–2525CrossRefPubMed Huang ZY, Liang BY, Xiong M et al (2012) Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann Surg Oncol 19:2515–2525CrossRefPubMed
19.
Zurück zum Zitat Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474CrossRefPubMed Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474CrossRefPubMed
20.
Zurück zum Zitat Okusaka T, Nakachi K, Fukutomi A et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103:469–474CrossRefPubMedPubMedCentral Okusaka T, Nakachi K, Fukutomi A et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103:469–474CrossRefPubMedPubMedCentral
Metadaten
Titel
Long-Term Survival of Recurrent Intrahepatic Cholangiocarcinoma: The Impact and Selection of Repeat Surgery
verfasst von
Tomoaki Yoh
Etsuro Hatano
Satoru Seo
Yukihiro Okuda
Hiroaki Fuji
Yoshinobu Ikeno
Kojiro Taura
Kentaro Yasuchika
Hideaki Okajima
Toshimi Kaido
Shinji Uemoto
Publikationsdatum
07.12.2017
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 6/2018
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-4387-7

Weitere Artikel der Ausgabe 6/2018

World Journal of Surgery 6/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.